Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
Ask the Experts

Ask the Experts

Experts from the CDC Answer Questions About Vaccines

Vaccine Index
Topic index
View All
Meet the Experts
From the National Center for Immunization and Respiratory Diseases at CDC, introducing
Medical Officer Andrew T. Kroger, MD, MPH
Nurse Educator Donna L. Weaver, RN, MN
Submit a Question: Ask the Experts
You can email your question about vaccines or immunization to IAC. We will respond to your email inquiry.
 
Related Materials from IAC
IAC Express
Needle Tips
Vaccinate Adults
Subscribe
What's New - Q&As
 
Love the Question of the Week?
Receive it every week in your email box
>> Subscribe to IAC Express!
QUESTION: A provider has a 54-year-old woman with rheumatoid arthritis who had been on etanercept (Embrel) at a dose of 50 mg per week. The etanercept was stopped two weeks ago. What is the interval between stopping etanercept and receiving zoster vaccine?
ANSWER: The safety and efficacy of zoster vaccine administered concurrently with recombinant human immune mediators and immune modulators (such as the anti-tumor necrosis factor agents adalimumab, infliximab, and etanercept) is not known. It is preferable to administer zoster vaccine before treatment with these drugs. Otherwise, administration of zoster vaccine (and other live vaccines) should be deferred for at least one month after discontinuation of treatment.
Question of the Week Archive
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000589) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.